Cytokinetics(US:CYTK) Globenewswire·2025-10-08 14:40Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Cytokinetics, Incorporated due to misleading statements regarding the New Drug Application (NDA) for aficamten, which may have led to investor losses [3][5][6]. Group 1: Legal Investigation - The firm is reminding investors of the November 17, 2025 deadline to seek the role of lead plaintiff in a federal securities class action against Cytokinetics [3]. - Investors who suffered losses between December 27, 2023, and May 6, 2025, are encouraged to discuss their legal rights with the firm [1][3]. Group 2: Misleading Statements - The complaint alleges that Cytokinetics made materially false statements about the NDA submission timeline and FDA approval expectations, specifically indicating a PDUFA date of September 26, 2025, without disclosing risks related to the omission of a Risk Evaluation and Mitigation Strategy (REMS) [5][6]. - During a May 6, 2025 earnings call, it was revealed that the company had discussions with the FDA regarding safety monitoring but chose to submit the NDA without a REMS, misleading investors about the regulatory timeline [6]. Group 3: Impact on Investors - As a result of the misleading statements, investors purchased Cytokinetics' stock at inflated prices and faced significant losses when the truth about the NDA submission was disclosed [7].